Medicare Enrolled
Dr. Jerry Hsieh, M.D.
Critical Care Medicine · Fountain Valley, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Hsieh from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hsieh?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Hsieh
Dr. Jerry Hsieh is a critical care medicine specialist in Fountain Valley, CA, with 14 years of NPI registration. Based on federal Medicare data, Dr. Hsieh performed 2,472 Medicare services across 983 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hsieh received a total of $18,934 from 42 pharmaceutical and/or device companies across 735 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in critical care medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hsieh is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years in practice
▲ Top 12% volume in CA
$18,934 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,472
Medicare services
Top 12% in CA for critical care medicine
983
Unique beneficiaries
$118
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~177 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,074 | $100 | $773 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
646 | $177 | $1,635 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
291 | $110 | $1,005 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
92 | $76 | $710 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
90 | $145 | $1,499 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
53 | $140 | $1,294 |
| Additional 30 minutes of critical care This code represents an additional 30 minutes of critical care services provided beyond the initial critical care time period. |
47 | $89 | $821 |
| Ultrasound guidance for blood vessel access Use of ultrasound imaging to help locate and access a blood vessel. This guidance assists healthcare providers in performing procedures such as inserting IV lines or drawing blood. |
19 | $12 | $103 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
17 | $35 | $175 |
| Lung volume measurement test A test that measures the largest amount of air you can breathe in and out. It evaluates the total capacity of your lungs. |
17 | $13 | $59 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
17 | $29 | $165 |
| Inhalation treatment for airway obstruction or sputum production A treatment involving the inhalation of medication to help clear airway obstructions or reduce sputum production. |
17 | $8 | $35 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
17 | $50 | $76 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
17 | $52 | $76 |
| Albuterol inhalation solution, 1 mg A unit dose of FDA-approved albuterol solution administered via durable medical equipment for inhalation. |
17 | $0 | $25 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
16 | $154 | $1,398 |
| Bronchial irrigation and suction for cell collection This procedure uses an endoscope to flush and suction the lung airways in order to collect cells for testing. |
13 | $73 | $1,012 |
| Arterial line insertion A tube is inserted into an artery through the skin to allow for blood sampling or infusion. |
12 | $36 | $330 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$18,934
Total received (2018-2024)
Avg $2,705/year across 7 years
Top 7% in CA for critical care medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
735
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$18,845 (99.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$89 (0.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,023
2023
$4,631
2022
$3,884
2021
$2,626
2020
$1,336
2019
$816
2018
$1,618
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$782
AstraZeneca Pharmaceuticals LP
$662
Regeneron Healthcare Solutions, Inc.
$637
GENZYME CORPORATION
$320
Mylan Specialty L.P.
$273
Pulmonx Corporation
$210
Boehringer Ingelheim Pharmaceuticals, Inc.
$187
Amgen Inc.
$145
Insmed, Inc.
$117
Takeda Pharmaceuticals U.S.A., Inc.
$115
Merck Sharp & Dohme LLC
$110
Grifols USA, LLC
$89
SANOFI-AVENTIS U.S. LLC
$89
United Therapeutics Corporation
$86
Vifor Pharma, Inc.
$75
Gilead Sciences, Inc.
$74
Inari Medical, Inc.
$29
Phadia US Inc.
$24
Top 3 companies account for 51.7% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$4,942
AstraZeneca Pharmaceuticals LP
$3,316
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,123
Regeneron Healthcare Solutions, Inc.
$1,816
Mylan Specialty L.P.
$944
GENZYME CORPORATION
$632
Amgen Inc.
$594
Grifols USA, LLC
$539
United Therapeutics Corporation
$443
Actelion Pharmaceuticals US, Inc.
$408
Philips Electronics North America Corporation
$384
Inari Medical, Inc.
$321
Pulmonx Corporation
$246
Gilead Sciences, Inc.
$232
Insmed, Inc.
$211
PFIZER INC.
$199
E.R. Squibb & Sons, L.L.C.
$151
Takeda Pharmaceuticals U.S.A., Inc.
$150
Genentech USA, Inc.
$136
SANOFI-AVENTIS U.S. LLC
$113
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$111
Merck Sharp & Dohme LLC
$110
La Jolla Pharmaceutical Company
$91
Vifor Pharma, Inc.
$75
Novartis Pharmaceuticals Corporation
$67
Intuitive Surgical, Inc.
$57
Baxter Healthcare
$52
Shire North American Group Inc
$49
Electromed, Inc.
$47
Advanced Respiratory, Inc
$46
Nabriva Therapeutics, plc
$43
Ambu Inc.
$39
Inogen, Inc.
$36
Allergan, Inc.
$32
Harmony Biosciences LLC
$27
Janssen Pharmaceuticals, Inc
$25
Phadia US Inc.
$24
Olympus America Inc.
$23
ADVANCED RESPIRATORY, INC
$22
Fisher & Paykel Healthcare Inc
$21
Itamar Medical Inc
$19
AbbVie Inc.
$15
Top 3 companies account for 54.8% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · 120V · 60Hz · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · CHANTIX · CHARTIS CATHETER · CINRYZE · CUVITRU · DUPIXENT · Da Vinci Surgical System · Dymista · ELIQUIS · Esbriet · FARXIGA · FASENRA · FISHER & PAYKEL HEALTHCARE · FLOWTRIEVER CATHETER · GIAPREZA · GLASSIA · HYQVIA · Hillrom - Life 2000 Ventilation System · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · ImmunoCAP · InogenOne · Life 2000 Ventilation System · LifeVest · NUCALA · OFEV · OPSUMIT · ORENITRAM · Perforomist · Prolastin-C · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · S · S&RC Und · SMARTVEST · SPIRIVA · SPIRIVA RESPIMAT · SPiN Thoracic Navigation System · STIOLTO RESPIMAT · SYMBICORT · TAGRISSO · TAVNEOS · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TYVASO · The Monarch Airway Clearance System · Trilogy 100 · UPTRAVI · Veklury · WAKIX · WINREVAIR · WatchPAT · XARELTO · XOLAIR · Xenleta · Xolair · YUPELRI · Yupelri · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 7% for critical care medicine in CA.
Geographic Context
Critical care medicines within 10 mi
68
Per 100K population
2.1
County median income
$113,702
Nearest hospital
UCI HEALTH - FOUNTAIN VALLEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Hsieh is a clinical cardiology specialist, with above-average Medicare volume (top 12% in CA), with low-engagement industry engagement in the top 7% of CA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Hsieh experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Hsieh performed 1,074 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hsieh receive payments from pharmaceutical companies?
Yes. Dr. Hsieh received a total of $18,934 from 42 companies across 735 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hsieh's costs compare to other critical care medicines in Fountain Valley?
Dr. Hsieh's average Medicare payment per service is $118. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hsieh) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Critical Care Medicines in Fountain Valley
Browse critical care medicines in Fountain Valley ranked by procedure volume and transparency data.
Highest volume
Top Critical Care Medicines in CA
Critical care medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Critical Care Medicines in CA
Which CA critical care medicines receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology